Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.

Adjusted time to next therapy: multivariate analysis After adjustment for baseline confounders to distinguish differences based on treatment effect, TTNT was longest among those treated with the newest Rd combination triplet, DRd, albeit the differences in risks of initiation of next line of therapy or death in patients treated with either VRd or IRd vs DRd in LOT ≥2 did not reach statistical significance ( P >0.05; Fig. 3 ).

also in 111,027 other papers